Featured Research

from universities, journals, and other organizations

Building a better drug to treat type 2 diabetes

Date:
October 9, 2012
Source:
University of Iowa Health Care
Summary:
Scientists have discovered a new biological pathway in blood vessel cells, which may contribute to the blood pressure-lowering effects of TZD drugs used to treat Type 2 diabetes. This finding may help to develop new therapies that retain the beneficial effect of TZDs but eliminate the adverse side effects.

Many drugs work by "fixing" a particular biological pathway that's gone awry in a disease. But sometimes drugs affect other pathways too, producing undesirable side effects that can be severe enough to outweigh the drug's benefits.

Such is the case for the thiazolidinedione drugs (also known as TZDs), which are used to treat type 2 diabetes. These are highly effective in controlling blood glucose levels and have an added benefit of lowering blood pressure in some patients. However, TZDs cause unrelated but potentially severe side effects in some patients, including heart failure, bone fracture, and to a lesser degree heart attack or bladder cancer depending on the specific TZD. The actual risks vary depending upon a patient's specific circumstances. Nonetheless, because of increased recognition of these unwanted effects, the rate of new TZD prescriptions is on the decline.

"We wanted to discover how TZDs lower blood pressure, so that more specific drugs might be developed that retain the beneficial effect of TZDs but eliminate the detrimental side effects," says Curt Sigmund, Ph.D., professor and head of pharmacology at the UI Carver College of Medicine, and senior author of a new study published Oct. 3 in the journal Cell Metabolism.

The TZD drugs activate a protein called PPAR-gamma. Genetic mutations in this protein disrupt the normal function of blood vessels and cause high blood pressure in people.

Sigmund and his colleagues wanted to home in on the function of PPAR-gamma in blood vessel, so they created a genetically modified mouse where the PPAR-gamma expressed in the blood vessels was mutated. These mice developed high blood pressure.

Using these mice to study how disruption of PPAR-gamma leads to high blood pressure, the researchers uncovered a new biological pathway (called the Cullin-3 pathway) in blood vessels, which may be the key to the blood pressure-lowering effects of TZD drugs.

The study showed that the activity of Cullin-3 in blood vessels is important for maintaining normal blood pressure, and decreased activity of Cullin-3, through disruption of PPAR-gamma, leads to increased blood pressure.

The study results may also help explain another recent finding that mutations in Cullin-3 cause early onset hypertension in people.

Sigmund notes that early research in mice has shown that new molecules, which target PPAR-gamma in new ways, do not have the side effects of TZDs. Whether these new drugs work through the Cullin-3 pathway identified by the UI team will require additional research, he says.

"Our study has added importance because some drugs, which target Cullin-3 and other Cullin proteins, are currently being tested as chemotherapies," adds Sigmund, who also directs the Center for Functional Genomics of Hypertension. "Our findings suggest that blood pressure will have to be monitored in patients undergoing these treatments."


Story Source:

The above story is based on materials provided by University of Iowa Health Care. Note: Materials may be edited for content and length.


Cite This Page:

University of Iowa Health Care. "Building a better drug to treat type 2 diabetes." ScienceDaily. ScienceDaily, 9 October 2012. <www.sciencedaily.com/releases/2012/10/121009112129.htm>.
University of Iowa Health Care. (2012, October 9). Building a better drug to treat type 2 diabetes. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2012/10/121009112129.htm
University of Iowa Health Care. "Building a better drug to treat type 2 diabetes." ScienceDaily. www.sciencedaily.com/releases/2012/10/121009112129.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins